Reviewing Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Zai Lab (NASDAQ:ZLAB)

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Eupraxia Pharmaceuticals and Zai Lab, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1	1	5	2	2.89
Zai Lab	1	1	4	1	2.71

Eupraxia Pharmaceuticals currently has a consensus price target of $18.00, suggesting a potential upside of 209.81%. Zai Lab has a consensus price target of $40.00, suggesting a potential upside of 108.12%. Given Eupraxia Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Zai Lab.

Profitability

This table compares Eupraxia Pharmaceuticals and Zai Lab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Zai Lab	-39.29%	-24.32%	-15.52%

Valuation and Earnings

This table compares Eupraxia Pharmaceuticals and Zai Lab”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58 million	($1.05)	-5.53
Zai Lab	$460.16 million	4.75	-$175.54 million	($1.62)	-11.86

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

41.6% of Zai Lab shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Eupraxia Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Summary

Eupraxia Pharmaceuticals beats Zai Lab on 9 of the 14 factors compared between the two stocks.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.